Health
BioMarin Announces Oral Presentation at ENDO2021, the Endocrine Society’s Annual Meeting, with Data Demonstrating 2 Years of Treatment Benefit in Children with Achondroplasia Treated with Vosoritide – PRNewswire
/PRNewswire/ — BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that data from the open-label long-term extension of the Phase 3 study of 15 µg/kg……
SAN RAFAEL, Calif., March 20, 2021 /PRNewswire/ — BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that data from the open-label long-term extension of the Phase 3 study of 15 µg/kg dose of vosoritide was presented at an oral presentation at ENDO21, the Endocrine Society’s Annual Meeting by Professor Ravi Savarirayan, M.B., B.S., M.D., clinical investigator from the Murdoch Children’s Research Institute, Royal Children’s Hospital, University of Melbourne, Parkville, Victoria. Vosoritide…
-
Noosa News21 hours agoTerrifying break-in at childcare centre on Sunshine Coast ends with death of man
-
General24 hours agoTrial of celebrity crocodile wrangler Matt Wright to hear from more witnesses
-
Noosa News19 hours agoADF to introduce billion-dollar drone dome over Brisbane 2032
-
Noosa News23 hours agoWhy the Story Bridge won’t have a traffic lane repurposed for bikes and walkers